SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario. The following posters will be presented:
